Улаанбаатар
2100 patients of Arkhangai aimag completely cured
Society
Ulaanbaatar/MONTSAME/. G.Zandanshatar,
Speaker of the Parliament, met with Ben Kamarck, Asia Pacific Regional Director
of U.S. pharmaceutical manufacturer ‘Gilead Sciences’, on May 23.
Gilead Sciences implemented
its ‘Access’ initiative to reduce liver disease in Mongolia. Within its
Arkhangai project -- a part of its Access initiative, Hepatitis C medication ‘Harvoni’
was provided free for the treatment of patients of Arkhangai aimag.
In total, 44 thousand people
of the aimag were screened, of whom 2100 were tested HCV positive. As a result
of the treatment, they have been completely cured.
Mr. Ben
Kamarck said, “The Arkhangai project has completed with successful implementation.
International health specialists commend that the project has been very
effective so that can be an example in Asia and the Pacific. We used to
implement this kind of project in other countries, but were not so successful
like an achievement we did in Arkhangai aimag. Therefore, it is important to promote
this experience throughout Mongolia and other countries.”
For his
part, Mr. Zandanshatar requested to continue the project throughout the
country.
In turn,
Mr. Kamarck said, “We intend to continue this project in one or two aimags, or
in the districts of Ulaanbaatar city. We will consult with the Ministry of
Health about it.”
